NEW YORK (GenomeWeb) – Mimetas, a developer of 3D disease- and tissue-modelling technologies, today said that it has raised $5.2 million in a private financing round to further develop its organ-on-a-chip technology platform.

Jos Joore, co-founder and chief business officer of the Leiden, Netherlands-based firm, said in a statement that the funds would be used to scale up production of Mimetas' OrganoPlates, which are used for 3D cell culture, and to "strengthen our activities in predictive preclinical model development."

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.

Sponsored by
Dovetail Genomics

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research. 

Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

Sponsored by
Dovetail Genomics

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.